Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-00990-7
Abstract: Somapacitan is a long-acting growth hormone (GH) derivative being developed for once-weekly dosing in patients with GH deficiency (GHD). Our objective was to evaluate the impact of kidney or hepatic impairment on somapacitan exposure in… read more here.
Keywords: hepatic impairment; group; impairment; function ... See more keywords
SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the Endocrine Society"
DOI: 10.1210/js.2019-sun-247
Abstract: Abstract Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden. Somapacitan is a long-acting GH derivative being developed for once-weekly dosing in adults and… read more here.
Keywords: efficacy safety; growth; treatment; somapacitan ... See more keywords
Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Endocrinology"
DOI: 10.1530/eje-21-1167
Abstract: Objective Growth hormone (GH) replacement therapy in patients with adult growth hormone deficiency (AGHD) is individually titrated due to variable dose–responses among patients. The aim of this study was to provide clinical guidance on dosing… read more here.
Keywords: exposure igf; somapacitan; dose exposure; igf response ... See more keywords
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1040046
Abstract: Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life. Daily subcutaneous injections with recombinant… read more here.
Keywords: growth; growth hormone; somapacitan; adult growth ... See more keywords